

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 June 2018 (21.06.2018)



(10) International Publication Number
WO 2018/111315 A8

(51) International Patent Classification:

C07D 401/04 (2006.01) A61P 29/00 (2006.01)
C07D 221/04 (2006.01) A61P 35/00 (2006.01)
C07D 401/12 (2006.01) A61P 37/00 (2006.01)
C07D 403/04 (2006.01) A61K 31/517 (2006.01)
C07D 413/04 (2006.01)

(21) International Application Number:

PCT/US2017/000094

(22) International Filing Date:

16 December 2017 (16.12.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/435,588 16 December 2016 (16.12.2016) US

(71) Applicant: **REATA PHARMACEUTICALS, INC.**
[US/US]; 2801 Gateway Drive, Suite 150, Irving, TX
75063-2648 (US).

(72) Inventors: **JIANG, Xin**; c/o 2801 Gateway Drive, Suite
150, Irving, TX 75063-2648 (US). **BENDER, Christo-
pher, F.**; c/o 2801 Gateway Drive, Suite 150, Irving, TX
75063-2648 (US). **VISNICK, Melean**; c/o 2801 Gateway
Drive, Suite 150, Irving, TX 75063-2648 (US). **HOTEMA,
Martha, R.**; c/o 2801 Gateway Drive, Suite 150, Ir-
ving, TX 75063-2648 (US). **SHELDON, Zachary, S.**; c/o
2801 Gateway Drive, Suite 150, Irving, TX 75063-2648
(US). **LEE, Chitase**; c/o 3915 Research Park Drive, Suite
A-1, Ann Arbor, MI 48108 (US). **CAPRATHE, Bradley**,


William; c/o 3915 Research Park Drive, Suite A-1, Ann Ar-
bor, MI 48108 (US). **BOLTON, Gary**; c/o 3915 Research
Park Drive, Suite A-1, Ann Arbor, MI 48108 (US). **KORN-
BERG, Brian**; c/o 3915 Research Park Drive, Suite A-1,
Ann Arbor, MI 48108 (US).

(74) Agent: **LONG, S., Reid**; Parker Highlander PLLC, 1120 S.
Capital of Texas Highway, Building One, Suite 200, Austin,
TX 78746 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR γ AND OTHER USES



(57) Abstract: Disclosed herein are compounds of the formulas: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to inhibit ROR γ and/or reduce the expression of IL-17. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or autoimmune disorders.

[Continued on next page]

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:

11 July 2019 (11.07.2019)

(15) Information about Correction:

see Notice of 11 July 2019 (11.07.2019)